Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT01366144)
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.
Who can join: Review the eligibility criteria below.
Location: City of Hope Comprehensive Cancer Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- City of Hope Comprehensive Cancer Center — Duarte, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- City of Hope South Pasadena — South Pasadena, California
- Moffitt Cancer Center — Tampa, Florida
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center-Weiler Hospital — The Bronx, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
- Case Western Reserve University — Cleveland, Ohio
- Penn State Milton S Hershey Medical Center — Hershey, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- UT MD Anderson Cancer Center — Houston, Texas
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Carcinoma
- Mobile Health for Adherence in Breast Cancer Patients — Fairbanks, Alaska
- An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction — Houston, Texas
- Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer — Houston, Texas
- HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics — Duarte, California
- A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation — Seattle, Washington
- Breast Cancer WEight Loss Study (BWEL Study) — Daphne, Alabama
Explore by condition: All Breast Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.